Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq®, in Kenya, including among HIV-infected and HIV-exposed infants
Authors:
- Kayla F. LasersonKLKayla F. Laserson
- Daveline NyakundiDNDaveline Nyakundi
- Daniel R. FeikinDFDaniel R. Feikin
- Geoffrey NyambaneGNGeoffrey Nyambane
- Earnest CookECEarnest Cook
- Janet OyiekoJOJanet Oyieko
- Joel OjwandoJOJoel Ojwando
- Stephen B. RiversSRStephen B. Rivers
- Max CiarletMCMax Ciarlet
- Kathleen M. NeuzilKNKathleen M. Neuzil
- Robert F. BreimanRBRobert F. Breiman
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Global Mortality Associated with Rotavirus Disease among Children in 2004The Journal of Infectious Diseases, 2009
- Diarrhea in children less than two years of age with known HIV status in Kisumu, KenyaInternational Journal of Infectious Diseases, 2009
- Rotavirus Infections among HIV-Infected Children in Nairobi, KenyaJournal of Tropical Pediatrics, 2009
- Rotarix: A Rotavirus Vaccine for the WorldClinical Infectious Diseases, 2009
- Efficacy of a pentavalent rotavirus vaccine in reducing rotavirus-associated health care utilization across three regions (11 countries)International Journal of Infectious Diseases, 2007
- Safety and Efficacy of a Pentavalent Human–Bovine (WC3) Reassortant Rotavirus VaccineNew England Journal of Medicine, 2006
- Global Illness and Deaths Caused by Rotavirus Disease in ChildrenEmerging Infectious Diseases, 2003
- Intussusception among Infants Given an Oral Rotavirus VaccineNew England Journal of Medicine, 2001
- A Prospective Study of Diarrhea and HIV-1 Infection among 429 Zairian InfantsNew England Journal of Medicine, 1993
- Diarrhea among African children born to human immunodeficiency virus 1-infected mothersThe Pediatric Infectious Disease Journal, 1992